Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Xalkori
| Field | Information |
|---|---|
| Medication Name | Xalkori |
| Generic Name | Crizotinib |
| Boxed/Label Warning | QT Interval Prolongation, Hepatotoxicity, Visual Disturbances, Pneumonitis |
| Purpose | Treatment of metastatic non-small cell lung cancer (NSCLC) whose tumors have either anaplastic lymphoma kinase (ALK) or ROS1 gene mutations. |
| Mechanism of Action | Inhibits ALK and ROS1 tyrosine kinases, blocking signaling pathways involved in cancer cell growth and survival. |
| Dosage Forms | Oral capsules |
| Available Strengths | 200 mg, 250 mg |
| Dosage Frequency | 250 mg orally twice daily |
| Common Side Effects | Vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated liver enzymes, fatigue, decreased appetite |
| Serious Side Effects | Pneumonitis, QT prolongation, hepatotoxicity, visual disturbances, bradycardia, pancreatitis, renal impairment |
| Drug Interactions | Strong CYP3A inhibitors (e.g., ketoconazole), strong CYP3A inducers (e.g., rifampin), CYP3A substrates, drugs that prolong the QT interval |
| Important Notes | Take exactly as prescribed. Do not open, crush, or chew the capsules. Avoid grapefruit and grapefruit juice. Regular monitoring of liver function, ECG, and vision is recommended. Inform your doctor about all medications and supplements you are taking. |
| Storage | Store at room temperature away from moisture and heat. |
| Missed Dose | If a dose is missed, take it as soon as you remember unless it is almost time for your next dose. Do not take two doses at the same time to make up for the missed dose. |
| Alternatives | Zykadia (ceritinib), Alecensa (alectinib), Tagrisso (osimertinib) |
Xalkori Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Zykadia (ceritinib) | ALK inhibitor | Used for ALK-positive NSCLC. |
| Alecensa (alectinib) | ALK inhibitor | Used for ALK-positive NSCLC, often as a first-line treatment. |
| Tagrisso (osimertinib) | EGFR inhibitor | Used for EGFR-positive NSCLC; not a direct alternative but used in NSCLC treatment. |
Xalkori Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Vision disorders (blurred vision, flashes of light) | Pneumonitis (inflammation of the lungs) |
| Nausea | QT prolongation (abnormal heart rhythm) |
| Diarrhea | Hepatotoxicity (liver damage) |
| Vomiting | Visual disturbances (vision loss, diplopia) |
| Edema (swelling) | Bradycardia (slow heart rate) |
| Constipation | Pancreatitis (inflammation of the pancreas) |
| Elevated liver enzymes | Renal Impairment |
Xalkori Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| ALK-positive NSCLC | 250 mg | 250 mg twice daily | Swallow capsules whole; do not crush or chew. Take with or without food. |
| ROS1-positive NSCLC | 250 mg | 250 mg twice daily | Swallow capsules whole; do not crush or chew. Take with or without food. |
